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Cost-Utility Analysis of Routine Anxiety and
Depression Screening in Patients Consulting for
Osteoarthritis: Results From a Clinical,
Randomized Controlled Trial
JESSE KIGOZI,1 SUE JOWETT,1 BARBARA I. NICHOLL,2 MARTYN LEWIS,3 BERNADETTE BARTLAM,3
DANIEL GREEN,3 JOHN BELCHER,3 KRIS CLARKSON,3 ZOE LINGARD,3 CHRISTOPHER POPE,3
CAROLYN A. CHEW-GRAHAM,3 PETER CROFT,3 ELAINEM. HAY,3 GEORGE PEAT,3 AND
CHRISTIAN D. MALLEN3
Objective. To investigate the cost-effectiveness (cost-utility) of introducing general practitioner screening for anxiety and
depression in patients consulting for osteoarthritis (OA).
Methods. A cluster-randomized trial-based economic evaluation to assess general practitioners screening for anxiety and
depression symptoms in patients consulting for OA compared to usual care (screening for pain intensity) was undertaken
over a 12-month period from a UK National Health Service and societal perspective. Patient-level mean costs and mean
quality-adjusted life years (QALYs) were estimated, and cost-effectiveness acceptability curves controlling for cluster-level
data were constructed. The base-case analysis used the net benefit regressions approach. The 2-stage nonparametric sam-
pling technique was explored in a sensitivity analysis.
Results. The base-case analysis demonstrated that the intervention was as costly as, and less effective than, the control
(QALY differential 0.029 [95% confidence interval 0.062, 0.003]). In the base-case analyses, general practitioner screen-
ing for anxiety and depression was unlikely to be a cost-effective option (probability <5% at £20,000/QALY). Similar results
were observed in all sensitivity analyses.
Conclusion. Prompting general practitioners to routinely screen and manage comorbid anxiety and depression in patients
presenting with OA is unlikely to be cost-effective. Further research is needed to explore clinically effective and cost-effec-
tive models of managing anxiety and depression in patients presenting with clinical OA.
INTRODUCTION
Osteoarthritis (OA) is a common cause of persistent pain,
disability, and poor quality of life in older adults. Estima-
tions are that approximately 1 million adults in the UK con-
sult for OA each year (1). OA has negatively impacted the
economy of the UK, with direct and indirect costs between
0.25% and 0.50% of gross national product (2,3). Direct
costs of OA treatment are driven mainly by total joint arthro-
plasty, while indirect costs are mostly driven by the loss of
productivity due to absenteeism from paid work (4,5).
Among other factors, persistent pain and disability-related
symptoms have been linked with increased levels of anxiety
and depression in patients with OA, who experience
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subsequent worse outcomes (6,7). Patients with OA and
associated depression use more medication and are likely to
have increased health care resource utilization (8,9). Depres-
sion is also a major cause of work-related absenteeism and
diminished or reduced productivity (10).
Case finding for depression in primary care has been rec-
ommended as a means of improving the identification of
depressive symptoms and consequently improving overall
quality of life and OA-related pain outcomes (11). Case
finding for depression in patients with a chronic physical
disease such as OA has been recommended in guidelines
by the National Institute for Health and Care Excellence
(NICE) (12,13), but these guidelines did not consider the
costs and benefits of such strategies. There have been calls
to investigate the effectiveness and cost-effectiveness of
case finding for anxiety and depression in patients with OA
in primary care (14), although to date, evidence of effective-
ness and cost-effectiveness remains limited (15–17).
We conducted an economic evaluation alongside a ran-
domized controlled trial (RCT) to establish the cost-effec-
tiveness of introducing general practitioner (GP) screening
for anxiety and depression in older patients consulting for
OA. The trial and its clinical findings have been reported in
full elsewhere (18). Here, we report the cost-effectiveness
(cost-utility) analysis, giving specific attention to a compar-
ison of alternative methodologic approaches to analyzing
cost-effectiveness data from clinical RCTs.
MATERIALS AND METHODS
Study overview. The economic evaluation took the form
of a cost-utility analysis alongside a clinical RCT over a 12-
month follow-up period. Randomization was conducted at
the GP practice level to prevent contamination between the 2
arms and participating GPs (19). The NHS perspective was
adopted in the base-case analysis. Ethical approval for this
study was obtained from the Black Country Research Ethics
Committee (#11/WM/0093), and all participants gave
informed consent to participate in the study. Primary care
resource data were obtained from reviewing medical records,
while secondary care resource use data were collected via
structured patient questionnaires at baseline and at 2 follow-
up points, 6 months and 12 months. Because the length of
follow-up was 12 months, neither costs nor outcomes were
discounted. The primary outcome for clinical effectiveness
was patient-reported current pain intensity on a 0–10
numerical rating scale (20), and the primary time point was
during 12 months after consultation. Full details of the trial
methods and results have been previously published (18).
Interventions. Patients in GP practices implementing
the intervention were screened by GPs at point-of-care for
anxiety, depression, and current pain intensity with the aid
of an electronic template linked with patient records,
which appeared following entry of a Read code for an OA-
related condition. The template incorporated a 2-item brief
depression tool (the Patient Health Questionnaire) (21), and
a 2-item ultrabrief anxiety assessment tool (the Generalized
Anxiety Disorder instrument) (22). Negative responses to
the anxiety and depression questions were used to rule out
a potential depression or anxiety diagnosis. The template
then prompted GPs to follow NICE clinical guidelines on
the management of OA, anxiety, and depression in patients
with physical health problems (23–25). The control
involved point-of-care current pain intensity assessment
prompted by the electronic template, but involving only the
item on current pain intensity. We calculated participant-
specific costs for the intervention based on information
collected within the trial. This calculation was made by
asking participating GPs about any additional time they
spent screening for anxiety and depression. Intervention
costs were then estimated, based on an average 1.29
additional minutes of GP time for screening participants
and based on a mean of the summary of responses from the
participating GPs in the GP questionnaire survey.
Outcome measures. We used the EuroQol 5-domain
instrument 5-level version (EQ-5D-5L), with a value estab-
lished using the UK value set derived from a UK general
population survey (26,27) to estimate quality-adjusted life
years (QALYs) gained using the area under the curve
approach (28). Imbalances in baseline EQ-5D-5L utility
scores were controlled for using a multiple regression–
based adjustment (29). This approach allows for estimation
of differential QALYs and facilitates prediction of adjusted
QALYs, while controlling for baseline utility values. The
model included the treatment arm dummy variable and
patient-specific baseline utility values (29). The primary
outcome for the trial was patient-reported current pain
intensity on a 0–10 numerical rating scale (19) across 12
months after consultation. All outcomes were measured at
baseline, 3 months, 6 months, and 12 months and were
obtained from a self-completed questionnaire administered
at these time points.
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Significance & Innovations
• This is the first economic evaluation assessing gen-
eral practitioner screening for anxiety and depres-
sion in older patients with osteoarthritis (OA) in
addition to screening for pain intensity.
• This economic evaluation showed that routine
screening for anxiety and depression by general prac-
titioners is unlikely to be cost-effective in patients
with OA.
• Further research is needed to explore cost-effective
models of managing anxiety and depression in
patients presenting with clinical OA.
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Resource use and costs. In the base-case analysis, costs
were measured from the UK NHS perspective, with overall
societal costs considered in the sensitivity analysis.
Information about resource use related to OA, anxiety, and
depression was collected from general practice records and
self-reported questionnaires. Primary care resource use was
obtained from a review of medical records covering the full
12-month follow-up period for patients who provided
consent, and included primary care contacts and prescribed
medications. Patient-level data on primary care consulta-
tions (from GP records) at which OA, anxiety, and/or
depression were mentioned were noted and recorded by
type of consultation and type of professional seen. Second-
ary care resource use data were collected via self-report
postal questionnaires administered at 6 months and 12
months. Secondary care contacts included visits to other
health care professionals (e.g., hospital consultants, physio-
therapists, counselors, and psychologists), hospital-based
investigations (e.g., radiographs, magnetic resonance
imaging scans), and procedures (injections, surgeries). Non-
NHS health care costs were assessed by obtaining
information on a patient’s purchase of over-the-counter
medicines, treatments, or appliances and their use of
private health care using postal self-report questionnaires.
Self-reported data on time off from work and occupation
were also collected to assess broader economic conse-
quences. Table 1 shows the unit costs and sources used to
value health care resources. Unit costs were obtained from
the published British National Formulary (30) for estimating
the cost of prescribed medication, and from the NHS
reference costs (31) and Unit Costs of Health and Social
Care (32) for primary and hospital-based resource use items.
Productivity costs were estimated using the human capital
approach, and salary costs were based on mean weekly
earnings by age and sex and UK Standard Occupational
Classification coding (33–35). All costs were expressed in
2013/2014 UK prices.
Statistical analysis. We explored the amount of each
resource used by patients in each group using frequencies
and mean  SDs. The statistical analysis was conducted on
an intent-to-treat basis and in accordance with current RCT
guidelines (36). The analysis involved adopting multilevel
modeling statistical techniques, taking into consideration
clustering in the cost-and-effect data (36,37). The multiple
imputation technique using predictive mean matching was
used to impute all missing values for the EQ-5D-5L and
cost data (38). The imputation model included age, sex,
and treatment group, and was based on M = 25 imputed
data sets.
Separate generalized equation models, controlling for
clustering, were used to estimate the mean incremental
costs and QALYs for the intervention relative to the control.
Uncertainty was examined by estimating 95% confidence
intervals and cost-effectiveness acceptability curves
(CEACs), which link the probability of the GP screening
intervention being cost-effective to a range of potential
threshold values (k) that the health system may be willing
to pay per additional QALY gained (36,39,40). Dependent
variables in the multilevel models included costs, QALYs,
and net monetary benefits (NMBs), and model coefficient
estimates of differences in these variables were used as part
of the incremental analysis. Statistical analysis was per-
formed using Stata software, version 12 (41).
Cost-effectiveness analytical approach. In the base-
case analysis, CEACs were estimated using an NMB
regression approach (42). The NMB method allows costs
and outcomes to be considered on the same monetary scale.
NMB was defined as k 9 (D effecti)  D costi, where D
effecti = the incremental person-level outcome associated
with the screening intervention, D costi = the additional
costs due to screening for anxiety and depression, and k =
willingness to pay per unit of outcome gain. Using the
output, we plotted CEACs, showing the likelihood that the
screening intervention is cost-effective given different
assumptions about willingness to pay for outcomes. The
regression analysis adopted methods reflecting the cluster
randomized nature of the trial (36,37), by using a
regression-based model of net benefits, with general
practice as the cluster identifier.
Sensitivity analysis. Sensitivity analyses were perform-
ed to assess uncertainty and robustness of the findings.
First, CEACs were estimated by using a 2-stage nonpara-
metric bootstrapping technique for comparison purposes
(40,43). This approach accounts for clustering between the
hierarchical cost-and-effect data. The 2-stage bootstrapping
Table 1. Unit costs and data sources*
Health care resource Unit cost, £
Primary care†
GP consultation per 11.7 minutes 34
Practice nurse consultation per
hour
44
Nurse home visit per hour 60
Community physiotherapist per
hour
30
Secondary care contacts‡
Orthopedic surgeon 128
Rheumatologist 202
Massage therapist 49
Physiotherapist 49
Osteopathic care provider 49
Mental health nurse 34
Chiropractor 49
Psychiatrist 283
Psychologist 264
Intervention cost
Extra time to complete prompt:
1.29 minutes
2.91
Prescribed medication Patient-specific§
Medical investigations/
interventions
Patient-specific‡
Time off work Mean national wage
by age and sex¶
* Available at: http://www.ons.gov.uk. GP = general practitioner.
† Unit Cost of Health and Social Care 2013 (Personal Social
Services Research Unit).
‡ National Health Service reference costs schedule 2012/2013.
§ British National Formulary (2013).
¶ Annual Survey of Hours and Earnings.
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output from Stata reports the cost-effectiveness prob-
abilities for a range of potential threshold values used to
estimate the probability that the intervention was cost-
effective. Second, results were presented from a societal
perspective, taking into account productivity costs. Third,
a complete-case analysis was carried out to assess the
impact of missing cost and EQ-5D-5L data.
RESULTS
Overview. Overall, 45 general practices were
randomized, 24 to the control group and 20 to the
intervention group, with a mean practice list size of 7,397
and 5,850 in the control and intervention groups,
respectively. In all, 7,279 patients were identified as eligible,
and after appropriate exclusions, 2,042 patients were mailed
a postconsultation questionnaire. Individual participants
recruited from the intervention and control practices had
broadly similar characteristics. A summary of participation
rates, by arm and by participant baseline characteristics, is
shown in Supplementary Tables 1 and 2, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23568/abstract. A total of 1,412
participants returned questionnaires from 20 intervention
practices (n = 501; 35%) and from 24 control practices (n =
911; 65%) and were considered for the base-case analysis.
Complete primary care resource data from GP records were
available for 1,235 participants (87%), while complete
secondary care resource data were available for 985
participants (70%) who returned questionnaires at both 6
and 12 months. Complete QALY data at baseline, 6 months,
and 12 months were available for 573 intervention
participants (63%) and 307 control participants (61%).
Following the multiple imputation procedure, all 1,412
participants were included in the base-case analysis. The
mean age of participants was 65 years, with slightly more
women (57%), who were overwhelmingly white (97%),
with just over 30% in paid employment.
Resource use. Table 2 shows the disaggregated details
of mean resource use for participants with complete re-
source use data. Service use was summarized under broad
categories, and individual items of service use were not
imputed. There were minimal differences between the 2
groups in terms of health care use, but the number of GP
visits for depression, anxiety, and OA was slightly higher
among intervention participants (2.86 versus 2.42), as were
visits to other NHS professionals for any reason (0.26
versus 0.13). Similar findings were observed when consid-
ering a societal perspective, with the exception of signifi-
cantly higher reported time off from work in the control
group at 12 months (15 days versus 8.3 days).
Health care costs and productivity costs. Table 2
summarizes the mean cost per patient, by group, for each
category of cost. All available data are included for each
category. Comparing the 2 groups, we found small
differences in the costs, with the exception of significant
differences in costs from other health care professionals
Table 2. Health care resource use and costs by trial arm*
Resource use, units Cost, £
Resource/cost component
Control
(n = 633)
Intervention
(n = 352)
Control
(n = 633)
Intervention
(n = 352)
Primary care†
General practitioner 2.42  2.07‡ 2.86  2.25‡ 80.92  68.19 94.38  73.23
Practice nurse 0.03  0.18 0.03  0.17 0.23  1.57 0.27  1.55
Other 0.07  0.34 0.04  0.20 – 0.14  1.67
Secondary care appointments§
NHS consultant 2.07  4.38 1.69  2.94 134.93  262.94 112.45  207.82
Private consultant 0.44  1.93 0.41  1.70 23.48  104.19 21.13  80.89
Other professionals, NHS hospitals 0.13  0.53‡ 0.26  1.24‡ 10.58  36.41 17.48  48.47
Other professionals, private hospitals 0.06  0.56 0.05  0.50 0.07  1.74 0.25  3.31
Investigations and treatments§ 372 (58.8)¶ 197 (55.9)¶ 377.21  1,153.01 353.33  1,014.55
Prescriptions
Anti-anxiety/anti-depression drugs, no. (%) 150 (19) 100 (23) – –
OA drugs, no. (%) 567 (71) 343 (78) – –
Prescribed medication – – 225.49  205.80 225.59  190.22
Over-the-counter medicines/treatments§ 373 (58.9)¶ 201 (57.10)¶ 13.55  50.29 14.10  58.46
Productivity loss/costs# 15.01  31.96 8.34  16.95 1,094.87  2,530.32 644.25  1,460.85
Productivity costs** – – 310.74  1,441.57 174.59  816.72
* Values are the mean  SD per patient, by treatment group, for patients providing health care utilization data, unless indicated otherwise.
† Data based on medical records review of available data and include anxiety/depression and OA-related health care use.
‡ Significant differences between the groups, because the value zero is not contained in the 95% confidence interval. Confidence intervals for mean
differences in resource use were obtained by bias-corrected and accelerated nonparametric bootstrapping, using 1,000 replications.
§ Data based on self-reported questionnaires at 6 and 12 months and include secondary health care use for any health reason.
¶ Number (%) of participants reporting usage are given instead of mean  SD because of multiple usage, purchases, and/or prescriptions over 12
months.
# Indirect costs based on the subsample of respondents in paid employment at 12 months (n = 280).
** Indirect costs based on the complete-case data set (n = 985).
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(such as occupational therapists, acupuncturists, and chiro-
practors) and from productivity loss. NHS, health care, and
societal costs were similar in both groups, although slightly
higher in the control arm. Adjusting for clustering in costs
resulted in negligible differences between the groups.
At 12 months of follow-up, 98 in the intervention group
(26.4%) and 182 in the control group (28.2%) were in paid
employment. Of those reporting being employed, 75 pa-
tients (11.6%) in the intervention group reported time off
from paid work compared with 35 (9.4%) in the control
group. Over a period of 12 months of follow-up, the mean
days taken off from work was higher in the control arm
(15.0 days) than the intervention arm (8.3 days), and this
difference translated to higher productivity costs in the
control arm compared to the intervention arm (Table 2).
Health outcomes and estimation of cost-effectiveness.
The results for analysis of the health outcome measures
(mean EQ-5D-5L scores and QALYs) are shown in Table 3.
In terms of QALYs gained at 12 months, the mean
estimates were 0.686 for the screening intervention and
0.711 for the control, showing higher QALY scores for the
control group after adjusting for baseline differences. A
similar result was observed in the unadjusted QALY
scores.
Estimation of cost effectiveness. Estimates showed that
the intervention was associated with lower QALYs and that
the adjusted difference in cost between the 2 groups was
minimal (£1.02 lower in the intervention arm). The mean
cost and outcome results of the cost-utility analysis based on
the net monetary benefit approach and forming the base-case
analysis are shown in Tables 3 and 4. The findings indicate
that there is a very low probability (<10%) of the intervention
being cost-effective at conventional willingness-to-pay thresh-
olds for additional QALYs (£20,000 to £30,000 per QALY).
Figure 1 shows the probability that the screening inter-
vention would be seen as cost-effective using a CEAC for
different values of willingness to pay from an NHS and
societal perspective–based net monetary benefit approach.
Sensitivity analysis results. Similar results were ob-
served when using the 2-stage nonparametric bootstrap ap-
proach. The probability of the intervention being cost-
effective remained low (<10%) at a conventional willingness-
to-pay threshold for additional QALYs. The output results
from this approach were, however, slightly lower than the net
monetary benefit approach (Figure 2). The analysis
conducted from a societal perspective showed that results
were broadly similar to the findings in the base-case analysis
(Figures 1 and 2). The results from the complete-case
sensitivity analysis are shown in Supplementary Table 3 and
in Supplementary Figures 1 and 2, available on the Arthritis
Table 3. Cost-utility analysis using the net benefit regression approach*
Control
(n = 911)
Intervention
(n = 501)
Incremental analysis,
intervention vs. control,
mean differences (95% CI)†
Cost analysis, £
NHS cost 759.74  1152.38 744.09  1008.36 1.02 (135.96, 138.02)
Health care cost 794.73  1163.13 777.75  1031.82 2.70 (138.28, 143.69)
Societal cost 1071.69  1866.80 946.34  1351.82 122.29 (318.50, 73.91)
Effectiveness analysis
Unadjusted QALYs gained 0.715  0.216 0.679  0.220 0.029 (0.062, 0.003)‡
Adjusted QALYs gained 0.711 0.686 –
* Values are the mean  SD unless indicated otherwise. Data set is imputed. 95% CI = 95% confidence interval; QALY = quality-adjusted life year.
† Mean differences adjusted for clustering in cost and QALY outcomes.
‡ P = 0.072.
Table 4. Cost-effectiveness analysis using the net
benefit regression approach, with probability that
treatment is cost effective at k*
Threshold value estimate NHS Societal
k = £0 51 89
k = £5,000 4 36
k = £10,000 3 16
k = £15,000 3 10
k = £20,000 3 8
k = £25,000 3 7
k = £30,000 3 6
k = £35,000 3 6
k = £40,000 3 5
* Values are the percentage. Data set is imputed. k = willingness
to pay per unit of outcome gain.
Figure 1. Cost-effectiveness acceptability curve for the compar-
ison of case finding versus pain only based on the net monetary
benefit regression approach. QALYs = quality-adjusted life
years.
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Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.23568/abstract. The results from these analy-
ses were generally consistent with the findings from the base-
case analysis, with the intervention as costly as but less
effective than the control. The only exception was that the
intervention was associated with a slightly higher probability
of being cost-effective (20%) in both approaches when com-
pared to the base-case analysis.
DISCUSSION
This study reports a cost-utility analysis of introducing GP
screening for anxiety and depression in older patients con-
sulting for OA, and an assessment of alternative analytical
approaches for economic evaluation of clinical RCTs. The
results showed that GP screening for anxiety and depres-
sion in OA patients is unlikely to be a cost-effective option,
and similar results are observed regardless of the perspec-
tive or approach adopted for the economic analysis. There
was minimal difference between the 2 groups in terms of
costs, and the finding that additional screening for anxiety
and depression is unlikely to be cost-effective is primarily
based on the evidence that shows slightly higher QALYs in
the control group. The results supplement the main trial
findings that found a small significant difference in the
direction of worse pain outcomes among those screened for
depression and anxiety compared to those not screened
(18). Further exploration of these results using probability
bias analysis suggests the results could plausibly be attrib-
uted to selection bias (44). In both analytical approaches
considered, probability of GP screening for anxiety and
depression being cost-effective remained low (<30%) at the
recommended NICE thresholds of £20,000 to £30,000 (45).
This is the first economic evaluation assessing GP screen-
ing for anxiety and depression in older people with OA in
addition to screening for pain intensity. The study was
based on a large sample of a wide range of patients with
clinically diagnosed OA (n = 1,412) across a number of
locations (45 practices). Resource use information was col-
lected using a combination of GP records and self-reported
data, including information outside the main NHS perspec-
tive, and therefore the study reports comprehensive
resource use data. However, a limitation of only using self-
report data is that respondents could potentially underre-
port resource utilization, particularly over longer periods of
recall (46,47). A further strength is that the use of the QALY
measure in the cost-effectiveness analysis may have cap-
tured a broader range of effects of screening than the pain
measure used in the clinical article, given that the EQ-5D-
5L used to generate the QALY measure includes dimen-
sions of pain, mobility, anxiety, and depression. In addi-
tion, the analysis used a pragmatic and rigorous study
design and employed comparative statistical methods for
analyzing cost-effectiveness data alongside cluster trials,
based on recommended methods (36,48).
However, there are also some limitations. The amount of
missing data in the primary care and secondary care data
requiring imputation may be of concern. Response rates for
the secondary care costs (70% at 12 months) and QALYs
(62% over 12 months) were relatively low. Multiple impu-
tation using predictive mean matching was used to address
potential biases resulting from incomplete data. However, a
limitation of this approach is that it does not take into con-
sideration the multilevel structure of the data. Moreover,
the imputation model specified could have included a
wider set of variables and covariates. Results of the base-
case (imputed) and complete-case analysis were compara-
ble in regard to policy implications.
Evidence supporting the effectiveness of screening for
anxiety and depression in patients with OA remains lim-
ited and with contradictory findings (14,18,49). No previ-
ous studies have assessed the cost-effectiveness of GP
screening for anxiety and depression in addition to screen-
ing for pain intensity in patients with OA at risk of depres-
sion. Our study, in line with findings from a previous
review (16), suggests that screening for anxiety and depres-
sion in general is unlikely to be a cost-effective option.
Few studies have attempted to compare alternative
methods for the economic analysis of clinical RCTs (48),
although methodologic guidance on the use of these
methods to analyze data from clinical RCTs has been
established. The analysis reported in this article showed
similar findings from the different approaches explored
(net monetary benefit approach and 2-stage bootstrap sam-
pling process). The results obtained here may not be gen-
eralizable to another disease or context. Further empirical
studies exploring alternative methods of analyzing clinical
RCTs in other disease areas or contexts are needed.
Our results show that patients receiving a screening inter-
vention for depression, anxiety, and pain intensity were
associated with higher primary care costs, but lower hospi-
tal and productivity loss costs. However, patients receiving
the screening intervention were associated with slightly
lower quality of life outcomes. The economic evaluation
demonstrated that adding routine screening for anxiety and
depression compared to usual care is not a cost-effective
option for patients with OA. The study has broader impli-
cations in depression case finding interventions targeted at
patients with OA, particularly with the assumption that
such services are money-saving to the NHS and improve
overall OA-related health outcomes. Here, productivity and
hospital cost savings were observed, but the probability of
overall cost-effectiveness was judged very low at recom-
mended incremental cost-effectiveness ratio thresholds.
Nonetheless, given the significant costs associated with
OA and the increased risks of anxiety and depression in
this group of patients, future research should explore the
Figure 2. Cost-effectiveness acceptability curve for the compar-
ison of case finding versus pain only based on the 2-stage boot-
strap sampling process. QALYs = quality-adjusted life years.
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costs and benefits of appropriate management strategies for
anxiety and/or depression once detected in patients pre-
senting with clinical OA in primary care. Assessing ways
of identifying those anxiety or depressive symptoms that
are likely to make future management services both less
cost-effective and more costly would also be helpful.
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